A Phase II dose escalation study of cyclophosphamide in haematopoietic stem cell transplantation in severe systemic sclerosis patients unfit for standard dose cyclophosphamide.
Phase 2
Recruiting
- Conditions
- Autoimmune disordersystemic sclerosis
- Registration Number
- ACTRN12617000216314
- Lead Sponsor
- St Vincent's Hospital Sydney
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cyclophosphamide's efficacy in haematopoietic stem cell transplantation for systemic sclerosis?
How does low-dose cyclophosphamide compare to standard-dose regimens in stem cell therapy for severe systemic sclerosis patients?
Which biomarkers predict response to cyclophosphamide-based haematopoietic stem cell transplantation in systemic sclerosis?
What are the potential adverse events associated with cyclophosphamide dose escalation in systemic sclerosis patients?
Are there combination therapies with cyclophosphamide that enhance haematopoietic stem cell transplantation outcomes in systemic sclerosis?